c-terminus

Gap19 is a peptide that corresponds to a sequence on the cytoplasmic loop (CL) of Cx43.

3X FLAG peptide consists of three repeating Asp-Tyr-Lys-Xaa-Xaa-Asp motifs with a FLAG tag at the C-terminus of the peptide.3X FLAG peptide can be used for protein identification and purification.

GLP-1(32-36)amide acetate is a pentapeptide and derived from the C terminus of the glucoregulatory hormone GLP-1. GLP-1(32-36)amide acetate could inhibit weight gain and modulate whole body glucose metabolism in diabetic mice.

Hsp70-derived octapeptide acetate (Hsp70-derived octapeptide acetate) is a group of tetratricopeptide repeat (TPR)-containing proteins has been shown to interact with the C-terminal domain of the 70 kDa heat-shock cognate protein (hsc70). In the present study, the effect of the TPR-containing proteins, including the C-terminus of hsc70-interacting protein (CHIP), TPR1 and human glutamine-rich TPR-containing protein (hSGT), on refolding of luciferase by DnaJ and hsc70 was investigated.

Rhodopsin Epitope Tag acetate is a 9-amino acid peptide representing C terminus of bovine rhodopsin widely used as an epitope tag. A number of anti-rhodopsin antibodies can recognize this epitope.

TR-100 is a small molecule inhibitor targeting tumor-associated tropomyosin (Tpm). It binds to the C-terminus of Tpm3.1, affecting its interaction with actin filaments and thus influencing their stability and function. This mechanism allows TR-100 to specifically affect actin filament bundles in cancer cells without impairing cardiac muscle function. TR-100 is useful for studying the role of Tpm3.1 in cancer cell proliferation and survival, as well as its impact on insulin-stimulated glucose uptake and insulin secretion.

His-ADPR is an immune signaling molecule produced by Toll/interleukin-1 receptor (TIR) domain proteins. Generated in response to phage infection, His-ADPR activates homologous Thoeris effectors by binding to the Macro domain located at the C-terminus of effector proteins.

pep2m aceate is a Peptide inhibitor of the interaction between the C-terminus of the GluR2 subunit and N-ethylmaleimide-sensitive fusion protein

Transdermal Peptide is a 11-amino acid peptide, binds to Na+/K+-ATPase beta-subunit (ATP1B1), and enhances the transdermal delivery of many macromolecules. Transdermal Peptide (TD1) binds to ATP1B1, and mainly interacts with the C-terminus of ATP1B1 in yeast and mammalian cells. The interaction affects the expression and localization of ATP1B1 and epidermal structure, but can be antagonized by the exogenous competitor ATP1B1 or be inhibited by ouabain. Inhibition of Transdermal Peptide binding to ATP1B1 causes decreased delivery of macromolecular drugs across the skin[1]. [1]. Wang C, et al. Role of the Na(+)/K(+)-ATPase beta-subunit in peptide-mediated transdermal drug delivery. Mol Pharm. 2015 Apr 6;12(4):1259-67.

Transdermal Peptide Disulfide TFA (TD 1 Disulfide(peptide) TFA), an 11-amino acid peptide, specifically binds to the Na+/K+-ATPase beta-subunit (ATP1B1), primarily interacting with its C-terminus, and enhances the transdermal delivery of various macromolecules[1].

GLP-1(32-36)amide is a pentapeptide compound derived from the C terminus of the glucoregulatory hormone GLP-1. This compound has shown potential in inhibiting weight gain and regulating glucose metabolism in diabetic mice[1][2].

'3'-Deoxy-3'-amino-ATP, an ATP analogue, is a highly effective and competitive inhibitor of ATP with a K i value of 2.3 μM. Its applications include the synthesis of 3'-Amino-3'-deoxy transfer RNA by integrating it into the 3' terminus of [tRNA-C-C].

Histone H3 (116-136), also known as C116-136, is a peptide comprising amino acids 116 to 136 of the C-terminus of histone H3.

PDZ1 Domain Inhibitor Peptide TFA, a cyclic peptide featuring a β-Ala lactam side chain linker, specifically targets the PDZ1 domains of postsynaptic density protein 95 (PSD-95). It effectively disrupts the GluR6/PSD-95 interaction, competing against the C terminus of GluR6 for the PDZ1 domain with high efficiency [1].

GR231118 TFA, a neuropeptide Y C-terminus analogue, acts as a potent, competitive, and relatively selective antagonist at the human neuropeptide YY receptor, exhibiting a pKi of 10.4. It serves as a strong agonist at the human neuropeptide YY4 receptor with a pEC50 of 8.6 and a pKi of 9.6, while demonstrating weak agonistic activity at both human and rat neuropeptide YY2 and YY5 receptors. Additionally, this compound shows high affinity for the mouse neuropeptide YY6 receptor, with a pKi value of 8.8 [1].

Cenderitide, a natriuretic peptide (NP) that combines C-type natriuretic peptide (CNP) with the C-terminus of Dendroaspis natriuretic peptide (DNP), serves as a potent agonist of the particulate guanylyl cyclase receptor (pGC). By activating both pGC-A and pGC-B receptors, it stimulates the production of the second messenger cGMP, suppresses aldosterone, and maintains glomerular filtration rate (GFR) without affecting blood pressure. This compound is particularly significant in the context of heart failure research, as evidenced by references [1] [2] [3].

Casein Kinase 2 Substrate Peptide, a widely recognized CK2 substrate, is synthesized with its C-terminus conjugated to 5-[(2-aminoethyl)amino]naphthalene-1-sulfonic acid (EDANS). This peptide serves as a tool for determining protein kinase CK2 activity [1].

Amylin (1-37) (human) (hIAPP (1-37)), a peptide hormone located in pancreatic beta-cell secretory granules, is characterized by an amidated C-terminus and a disulfide bond between cysteine residues 2 and 7 [1].

[Sar4] Substance P (4-11) is a Substance P agonist and an analog of the C-terminus fragment of Substance P known as Substance P (4-11) [1].

Ponezumab (PF-04360365) is a humanized monoclonal antibody targeting the C-terminus of beta-amyloid 40 (Abeta40). By binding to Abeta40 in the blood, it establishes a 'peripheral sink' effect, thereby promoting the transfer of amyloid proteins from the central nervous system to the periphery and reducing brain plaque burden. It is primarily used for pharmacological research in Alzheimer's disease and cerebral amyloid angiopathy.

Sudubrilimab is an innovative bifunctional fusion protein designed to simultaneously target two key inhibitory pathways in the tumor microenvironment: the PD-1/PD-L1 immune checkpoint and the TGF-beta signaling axis. The compound consists of a humanized anti-PD-L1 monoclonal antibody fused to the extracellular domain of TGF-beta receptor II (TGFBR2-ECD). Serving as an essential tool for investigating the reversal of tumor immunosuppression and the enhancement of effector cell function, its design aims to overcome resistance to single-target therapies through synergistic action.

Epsilon-V1-2, a Cys-conjugated, is a biologically active peptide known as the εPKC-specific inhibitor. It hampers εPKC functionality by obstructing its translocation and the phosphorylation of MARCKS, additionally perturbing εPKC's interaction with its anchoring protein, εRACK. The peptide includes a cysteine residue at its C-terminus, facilitating the formation of potential disulfide bonds with carrier proteins. Pyroglutamyl formation can occur spontaneously at the N-terminus if glutamine or glutamic acid is present, enhancing peptide stability against gastrointestinal proteases. Pyroglutamyl peptides, a recognized subset, are accounted for in the peptide's purity during HPLC analysis.

C5a Receptor Agonist (mouse, human) is a bioactive peptide derived from the C-terminus of the complement fragment 5 anaphylatoxin (C5a), functioning as an agonist for the C5a receptor. This peptide plays a role in mediating inflammatory responses by promoting chemotaxis, leukocyte degranulation, enhanced vascular permeability, and cytokine production. Its agonistic activity is critically dependent on the presence of cyclohexylalanine at position 5 and the d-isomer of Arg at the terminal position.

C5aR1 antagonist peptide, a biologically active linear peptide originating from the C-terminus of the chemokine complement fragment 5 anaphylatoxin (C5a), inhibits C5a binding and activity at human and rat C5a receptors. Overexpression of C5a is linked to various immunoinflammatory diseases, including arthritis, Alzheimer's disease, cystic fibrosis, and systemic lupus erythematosus.